177 related articles for article (PubMed ID: 27992550)
1. Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
Diessner J; Wischnewsky M; Blettner M; Häusler S; Janni W; Kreienberg R; Stein R; Stüber T; Schwentner L; Bartmann C; Wöckel A
PLoS One; 2016; 11(12):e0168730. PubMed ID: 27992550
[TBL] [Abstract][Full Text] [Related]
2. Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Herr D; Wischnewsky M; Joukhadar R; Chow O; Janni W; Leinert E; Fink V; Stüber T; Curtaz C; Kreienberg R; Blettner M; Wollschläger D; Wöckel A
PLoS One; 2019; 14(7):e0218434. PubMed ID: 31283775
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemotherapy Guidance in Young Breast Cancer Patients With Luminal Subtypes and Stage pT1N0.
Qiu J; Du Z; Wang Y; Zhou Y; Zhang J; Liu P; Lv Q
J Surg Res; 2019 Aug; 240():165-174. PubMed ID: 30951993
[TBL] [Abstract][Full Text] [Related]
4. Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Leinert E; Schwentner L; Janni W; Wöckel A; Herbert SL; Herr D; Kühn T; Flock F; Felberbaum R; Kreienberg R; Fink V; Dayan D; Ernst K; Singer S;
Breast Cancer; 2022 May; 29(3):429-436. PubMed ID: 35178667
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
6. Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients.
Wolters R; Ebner F; Janni W; Novopashenny I; Wöckel A; Kreienberg R; Wischnewsky M; Schwentner L;
Arch Gynecol Obstet; 2016 Aug; 294(2):377-84. PubMed ID: 26894302
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
Hetterich M; Gerken M; Ortmann O; Inwald EC; Klinkhammer-Schalke M; Eggemann H; Ignatov A
Breast Cancer Res Treat; 2021 Jun; 187(3):715-727. PubMed ID: 33721148
[TBL] [Abstract][Full Text] [Related]
8. Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
Taskaynatan H; Kucukzeybek Y; Alacacioglu A; Yildiz Y; Salman T; Oflazoglu U; Varol U; Bolat Kucukzeybek B; Kemal Atahan M; Oktay Tarhan M
J BUON; 2018; 23(4):877-882. PubMed ID: 30358189
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant systemic treatment of early breast cancer: the NORA study.
Cazzaniga ME; Mustacchi G; Pronzato P; De Matteis A; Di Costanzo F; Floriani I;
Ann Oncol; 2006 Sep; 17(9):1386-92. PubMed ID: 16790520
[TBL] [Abstract][Full Text] [Related]
10. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
11. The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?
Sun Y; Liu X; Cui S; Li L; Tian P; Liu S; Li Y; Yin M; Zhang C; Mao Q; Wang J
Tumour Biol; 2016 Jul; 37(7):9555-63. PubMed ID: 26790445
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
13. Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.
Taubenhansl C; Ortmann O; Gerken M; Inwald EC; Klinkhammer-Schalke M
Arch Gynecol Obstet; 2020 Feb; 301(2):573-583. PubMed ID: 31749031
[TBL] [Abstract][Full Text] [Related]
14. Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.
Ebner F; Wöckel A; Janni W; Kreienberg R; Schwentner L; Wischnewsky M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1823-1831. PubMed ID: 28439713
[TBL] [Abstract][Full Text] [Related]
15. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
Yang H; Zhou L; Wang S; Cao Y; Tong F; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Guo J; Wang S; Peng Y
Medicine (Baltimore); 2018 Oct; 97(40):e12690. PubMed ID: 30290661
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
